Article Text

Download PDFPDF
Case report
Clenbuterol: a new toxic substance in paediatrics
  1. Andrew A Tester,
  2. Sheena Logan,
  3. Louisa Pollock and
  4. Allison McKie
  1. Emergency Department, Royal Hospital for Children, Glasgow, Scotland, UK
  1. Correspondence to Dr Andrew A Tester; andrewtester3291{at}


A 13-year-old girl presented to the emergency department with acute onset of chest pain, nausea and tremor. The patient denied drug ingestion, and urine toxicology was negative. ECG demonstrated sinus tachycardia, prolonged QTc (541 ms) and ST depression. Laboratory testing demonstrated metabolic acidosis, hypokalaemia, hypophosphataemia and hyperglycaemia. She was commenced on continuous cardiac monitoring and treated with intravenous fluids and electrolyte replacement. Presenting features and laboratory abnormalities resolved within 48 hours. The National Poisons Information Service and Clinical Biochemistry were integral to her management, advising the clinical team on the likeliest aetiology. Five weeks after discharge, urine toxicology, using mass spectrometry, identified clenbuterol. Clenbuterol is an oral β2-agonist with anabolic and lipolytic effects that is misused as a performance and image enhancing drug. Clinicians must be aware of the increasing availability of these drugs and their potential for causing harm in children and adolescents.

  • poisoning
  • paediatrics
  • toxicology
  • paediatrics (drugs and medicines)
  • drug misuse (including addiction)

Statistics from


  • Contributors AAT planned and designed the manuscript, and liaised with the family to obtain consent for the publication. SL contributed to the design and editing of the manuscript. LP contributed to the editing of the manuscript and made initial contact with the family. AM contributed to the editing of the manuscript. All authors contributed to the clinical care of the patient during their admission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.